NxStage Medical Sells to Dialysis Giant Fresenius for $2B
Summary
NxStage Medical Sells to Dialysis Giant Fresenius for $2B Xconomy Boston — German dialysis giant Fresenius is paying $2 billion to acquire NxStage Medical, a Lawrence, MA-based developer of products for patients dealing with kidney failure.Fresenius is paying $30 a share for NxStage (NASDAQ: NXTM), a roughly 28 percent premium to the company’s $23.14 closing price on Friday.Fresenius operates nearly 3,700 dialysis clinics around the world, where patients with failing kidneys can go to have toxins and water removed from their blood.Peritoneal dialysis is a home treatment done via a catheter through the abdomen, and doesn’t require needles or bagged fluid.Baxter’s progress—it expects to file for regulatory approval of a system in 2019—combined with NxStage’s delay and slumping sales caused the latter’s shares to fall about 20 percent from its all-time highs in late April.
Classifications
AskAI Classifications
LabelsLinked Companies
